AGEN Research and Charts

AGEN - Agenus Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2024-08-12 (Delayed quote data 2025-04-02)

Last 1.63	Change ⇑ +0.03 (+1.87%)	Volume 274,052
	Open 1.56	High 1.63	Low 1.46

8EMA (Daily) 1.64	40EMA (Daily) 2.29	50EMA (Daily) 2.45	STO (Daily) 20.278	MACD Hist (Daily) 0.061
8EMA (Weekly) 2.184	40EMA (Weekly) 5.23	50EMA (Weekly) 6.59	STO (Weekly) 3.980	MACD Hist (Weekly) 0.124


Company Profile
Agenus Inc is an American biotechnology company. Its main target is immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multiple antibody platforms, to stimulate the immune system to recognize and fight cancer cells. The company has been cooperating with companies like Incyte, Merck Sharpe & Dohme, and Recepta Biopharma to achieve over a dozen antibody programs. Some of its products include Prophage, AutoSynVax, QS-21 Stimulon, and others.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.